Want to see FHTX full AI Analyst Report?
FHTX Stock Chart & Stats
$4.85
$0.35(7.22%)
At close: 4:00 PM EDT
$4.85
$0.35(7.22%)
Day’s Range― - ―
52-Week Range$3.27 - $6.95
Previous Close$5.36
Volume159.32K
Average Volume (3M)157.41K
Market Cap
$305.31M
Enterprise Value$189.51
Total Cash (Recent Filing)$184.88M
Total Debt (Recent Filing)$41.99M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Aug 11, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding58,713,920
10 Day Avg. Volume207,613
30 Day Avg. Volume157,412
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-3.13
Price to Sales (P/S)11.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.75Price Target Upside142.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.07
Revenue Forecast (FY)$26.76M
Bulls Say, Bears Say
Bulls Say
Strategic Partnership With Eli LillyA collaboration with Eli Lilly on the lead SMARCA2 program supplies external development expertise and validation of the science, reducing technical and commercialization risk. This durable partnership can accelerate clinical development and provide non-dilutive funding or milestone support as programs advance.
Broad, Advancing Oncology PipelineMultiple programs (SMARCA2, CBP, EP300, ARID1B) progressing to IND-enabling studies and showing strong preclinical activity diversify clinical risk. A platform producing several candidates increases the probability that at least one will reach later stages, supporting longer-term franchise value beyond a single asset.
Cash Runway Into First Half Of 2028A cash balance of $184M and runway into H1 2028 give the company multi-quarter financing visibility to complete IND-enabling work and early Phase 1 activities. This reduces immediate financing pressure and allows management to sequence programs and spend more strategically over the medium term.
Bears Say
Negative Stockholders' EquitySustained negative equity reflects accumulated losses that constrain financial flexibility and can increase future financing costs or dilute existing holders. Over months, negative equity can limit strategic options, complicate partnerships, and increase reliance on capital markets to fund ongoing R&D.
Persistent Operating Cash BurnRepeated negative operating and free cash flow means the company must repeatedly access external capital to fund operations. This structural cash burn drives dilution risk, constrains long-term planning, and makes sustained investment in multiple programs dependent on successful financing or partner milestones.
Volatile Revenue And Weakening MarginsRevenue volatility and a recent sharp gross margin decline reduce operating leverage and make the path to breakeven more uncertain. Over the medium term, weaker margins increase the amount of financing required to reach value-inflection points and heighten sensitivity to any further revenue or collaboration setbacks.
Foghorn Therapeutics News
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $3.27 and its highest was $6.95 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Foghorn Therapeutics’s market cap is $305.31M.
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 12 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on May 07, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.305 by $0.015.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 58,713,920 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.305. Following the earnings report the stock price went down -10.256%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Currently, no hedge funds are holding shares in FHTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Foghorn Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.75 (142.27% Upside)
$11.75 (142.27% Upside)
Hedge Fund Trend
Increased
By 904.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.12%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
FHTX Stock 12 Month Forecast
Average Price Target
$11.75
▲(142.27% Upside)
Technical Analysis
Ownership Overview
1.10% Insiders
10.49% Mutual Funds
0.04% Other Institutional Investors
82.24% Public Companies and
Individual Investors